Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Aggarwal

Showing results (181-190 of 262) with videos related to

Pageof 27
Sort By:
Clinical and Experimental Rheumatology|February 12, 2026
Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositisNantakarn Pongtarakulpanit, Anuradha Bishnoi, Tanya Chandra, et al.
ACR Open Rheumatology|September 21, 2022
Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and DermatomyositisChester V Oddis, Howard E Rockette, Lei Zhu, et al.
Annals of the Rheumatic Diseases|October 11, 2017
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trialAnna Tjärnlund, Quan Tang, Cecilia Wick, et al.
Rheumatology International|July 13, 2024
COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD studyAlessia Alunno, Francesco Carubbi, Ai Lyn Tan, et al.
Nature Reviews. Rheumatology|March 29, 2024
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiativeAlexander G S Oldroyd, Jeffrey P Callen, Hector Chinoy, et al.
Nature Reviews. Rheumatology|November 9, 2023
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiativeAlexander G S Oldroyd, Jeffrey P Callen, Hector Chinoy, et al.
The Journal of Clinical Investigation|July 21, 2020
Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathyKevin E McElhanon, Nicholas Young, Jeffrey Hampton, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Anti-Mi2 autoantibodies target the PHD fingers of SP140L and TIF1γ, while anti-TIF1γ autoantibodies primarily recognize epitopes outside the PHD region of TIF1γIago Pinal-Fernandez, Jon Musai, Maria Casal-Dominguez, et al.
Rheumatology (Oxford, England)|August 12, 2025
Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1γ, while anti-TIF1γ autoantibodies primarily bind TIF1γ outside the PHD regionIago Pinal-Fernandez, Jon Musai, Maria Casal-Dominguez, et al.
Journal of Diabetes Investigation|September 12, 2023
Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD studyTulika Chatterjee, Naveen Ravichandran, Narmadha Nair, et al.
Pageof 27

Showing results (181-190 of 262) with videos related to

Sort By:
Pageof 27
Clinical and Experimental Rheumatology|February 12, 2026
Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositisNantakarn Pongtarakulpanit, Anuradha Bishnoi, Tanya Chandra, et al.
ACR Open Rheumatology|September 21, 2022
Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and DermatomyositisChester V Oddis, Howard E Rockette, Lei Zhu, et al.
Annals of the Rheumatic Diseases|October 11, 2017
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trialAnna Tjärnlund, Quan Tang, Cecilia Wick, et al.
Rheumatology International|July 13, 2024
COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD studyAlessia Alunno, Francesco Carubbi, Ai Lyn Tan, et al.
Nature Reviews. Rheumatology|March 29, 2024
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiativeAlexander G S Oldroyd, Jeffrey P Callen, Hector Chinoy, et al.
Nature Reviews. Rheumatology|November 9, 2023
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiativeAlexander G S Oldroyd, Jeffrey P Callen, Hector Chinoy, et al.
The Journal of Clinical Investigation|July 21, 2020
Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathyKevin E McElhanon, Nicholas Young, Jeffrey Hampton, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Anti-Mi2 autoantibodies target the PHD fingers of SP140L and TIF1γ, while anti-TIF1γ autoantibodies primarily recognize epitopes outside the PHD region of TIF1γIago Pinal-Fernandez, Jon Musai, Maria Casal-Dominguez, et al.
Rheumatology (Oxford, England)|August 12, 2025
Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1γ, while anti-TIF1γ autoantibodies primarily bind TIF1γ outside the PHD regionIago Pinal-Fernandez, Jon Musai, Maria Casal-Dominguez, et al.
Journal of Diabetes Investigation|September 12, 2023
Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD studyTulika Chatterjee, Naveen Ravichandran, Narmadha Nair, et al.
Pageof 27